Expert Interview
A Second View: Discussing the recent Phase 1B data from Celldex on Barzolvolimab (CDX-0159) in treating Spontaneous Urticaria
Ticker(s): CLDXInstitution: Riviera Allergy Medical Center
- Allergist/Immunologist and founder of Riviera Allergy Medical Center in Redondo Beach, CA.
- Double board certified in both Allergy/Immunology and Pediatrics with clinical appointments at both City of Hope and Children's Hospital of Los Angeles.
- Reviewer for the Journal of Infectious Diseases and Clinical and Vaccine Immunology and has presented at both national and international medical conventions; has been the author and co-author of numerous peer-reviewed publications in national and international journals.
Roughly how many patients with urticaria do you currently manage?
What were your initial impressions of the recent Phase 1B data on CDX-1059?
Added By: c_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for CDX-0159?
Added By: c_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
